|
|
|
MRNA - Moderna, Inc
Moderna, Inc. (MRNA) is an American biotechnology company focused on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna's platform technology uses mRNA to instruct cells to produce proteins that can treat or prevent diseases. The company's product pipeline includes vaccines and therapeutics for a range of infectious diseases, cancer, and rare genetic disorders.
Moderna's most notable achievement to date has been the development of one of the first COVID-19 vaccines authorized for emergency use in the United States. The vaccine, known as the Moderna COVID-19 vaccine, was developed in partnership with the National Institutes of Health and has shown to be highly effective in clinical trials.
Moderna has also made significant investments in research and development, with a focus on developing new mRNA therapeutics and vaccines. The company has partnerships with several pharmaceutical and biotechnology companies, as well as government agencies, to advance its technology and product pipeline.
As of 2021, Moderna had a market capitalization of over $150 billion and was recognized as a leader in the field of mRNA technology. The company has been widely praised for its innovative technology and its contribution to the development of effective COVID-19 vaccines.
|
|
|
|
|
